ISRCTN82846830已完成不适用
Vascular function in polycystic ovary patients after treatment with metformin: its role in polycystic-ovary-syndrome-associated insulin resistance
Vrije University Medical Centre (VUMC) (The Netherlands)0 个研究点目标入组 40 人开始时间: 2006年2月14日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. PCOS as judged in early routine patient work-up by three out of the following four criteria:
- •1.1. Oligomenorrhoea (mean length of the menstrual cycle greater than 35 days) or amenorrhoea (based on history of oligomenorrhoea)
- •1.2. Evidence of hyperandrogenism, whether clinical (hirsutism, acne, or male pattern balding) or biochemical (elevated serum androgen level [total testosterone greater than 2 nmol/l, and/or androstedione greater than 9], determined in a period while the patient was not using any medication with potential endocrine influence)
- •1.3. Elevated serum leuteinising hormone (LH) level (greater than 6.5 IU/l), determined at least 2 weeks after the beginning of a menstrual period and 3 weeks before the subsequent menstrual period in the presence of a normal follicle-stimulating hormone (FSH) level (less than 10 IU/l, determined in a period while the patient was not using any medication with potential endocrine influence)
- •1.4. A polycystic ovary morphology (defined by the presence of eight or more subcapsular follicular cysts less than or equal to 10 mm and increased ovarian stroma) by ultrasound performed at our department
- •2. Aged 18 - 40 years
- •3. One phase combined oral contraceptives with 30 ethinylestradiol (preferred are Microgynon 30®, Stediril 30, Yasmin® and Diane® 35) for at least 3 months but no other medication to avoid hormonal cyclicity and for contraceptive purposes
- •4. Informed consent
排除标准
- •1. Cardiovascular disease (hypertension [greater than 160/90 mmHg], stroke, coronary artery disease, peripheral vascular disease, heart failure)
- •2. Diabetes mellitus (according to American Diabetes Association [ADA] criteria)
- •3. Hypothyroidism, hyperprolactinemia, Cushing's syndrome nonclassical congenital adrenal hyperplasia
- •4. Smoking for the last three months
- •5. Alcohol use greater than 4 units/day
- •6. Pregnancy
- •7. Diseases that influence reproductive hormone status
- •8. Kidney and liver dysfunction or congestive heart failure (which can cause lactic acidosis when taking metformin)
研究者
相似试验
已完成
不适用
Vascular function in polycystic ovary patients after treatment with metformin: it’s role in polycystic-ovary-syndrome-associated insulin resistance.polycystic ovary syndromeNL-OMON28442VU University Medical Center, Amsterdam, the Netherlands40
已完成
不适用
Follow-up study of patients with polycystic ovary syndrome for predicting risk factors of cardiovascular diseaseEndocrine, nutritional and metabolic diseaseKCT0000739Korea Centers for Disease Control and Prevention200
尚未招募
不适用
pcos study in women with different weightsCTRI/2022/11/047655Ambika
招募中
不适用
Influence of calcium and / or vitamin D supplementation in patients with Polycystic Ovarian Syndrome.Polycystic Ovarian Syndrome and Health VolunteersC04.182.612.765M01.774.500RBR-986tpdniversidade Federal de Minas Gerais - UFMG
进行中(未招募)
不适用
Effects of physical exercise on cholesterol, glycemia and menstrual cycle of women with micropolicistos in the ovaryRBR-6nhy6hDepartamento de Toco-Ginecologia da Universidade Federal do Rio Grande do Norte
